新型猪增生性肠炎灭活疫苗的效力评估
在三个实验性攻毒试验中,新型灭活疫苗Porcilis® Lawsonia与市售活疫苗及空白对照比较,显示对Lawsonia intracellularis攻毒具有显著保护作用,且优于活疫苗。现场研究中该疫苗将相关死亡率降至零并改善关键生产参数。
要点
- 灭活疫苗在实验攻毒中显著降低临床评分、排菌及肠道病变,保护力优于活疫苗。
- 现场条件下,该疫苗将Lawsonia相关死亡率降至零并改善关键生产指标。
- 疫苗抗原可溶于佐剂或与猪圆环病毒2型/猪肺炎支原体联合疫苗混合使用。
核心结论
- Porcilis® Lawsonia灭活疫苗在实验攻毒和现场条件下均对猪Lawsonia intracellularis感染具有显著保护效力。
研究设计与样本
- 三个实验性疫苗接种-攻毒试验,每个试验使用75头仔猪随机分为三组每组25头。
- 现场研究在有过急性回肠炎病史的农场评估8个月内的死亡率和关键生产参数。
主要发现
- 所有三个实验试验中,与对照组相比,Porcilis® Lawsonia组临床评分更低、增重改善、排菌减少、回肠宏观及微观病变评分降低。
- 诱导的保护力优于市售活疫苗。
- 现场研究中该疫苗高效,将Lawsonia相关死亡率降至零并改善关键生产参数。
临床怎么用
- 可用于预防猪Lawsonia intracellularis感染,既可单独与佐剂配合,也可与Porcilis® PCV M Hyo联合使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficacy of a novel inactivated Lawsonia intracellularis vaccine, Porcilis® Lawsonia, was compared to that of a commercially available live attenuated vaccine in three experimental vaccination-challenge studies in pigs. The efficacy of the new vaccine was further tested under field conditions on a farm with a history of acute ileitis. The novel inactivated vaccine consists of a freeze-dried antigen fraction that is dissolved just prior to use in either the adjuvant or in Porcilis® PCV M Hyo; an existing combination vaccine against porcine circovirus type 2 and Mycoplasma hyopneumoniae. The three experimental vaccination-challenge trials had a similar design and for each trial 75 piglets were used, randomly allotted to three groups of 25 piglets. The pigs were vaccinated at 4 or 5 weeks of age with either Porcilis® Lawsonia in adjuvant or in associated mixed use with Porcilis® PCV M Hyo (group 1), with the live vaccine (group 2), or left as unvaccinated controls (group 3). The pigs were challenged with virulent Lawsonia intracellularis 3, 4 or 17 weeks after vaccination. Post-challenge the pigs were evaluated for clinical signs, average daily weight gain, shedding and macroscopic as well as microscopic immuno-histological ileum lesion scores. In the field study, the mortality and key performance parameters were evaluated over a period of 8 months. The results of all three experimental vaccination-challenge trials showed that Porcilis® Lawsonia induced statistically significant protection against experimental Lawsonia intracellularis infection. This was demonstrated by lower clinical scores, improved weight gain, reduction of Lawsonia intracellularis shedding and reduction of macroscopic as well as microscopic ileum lesion scores when compared to the controls. The protection induced was superior to that of the commercially available live vaccine. In the field study, Porcilis® Lawsonia proved to be highly efficacious; reducing Lawsonia associated mortality to zero and improving key production parameters.
引用
- Jacobs AAC, Harks F, Hazenberg L, et al. Efficacy of a novel inactivated Lawsonia intracellularis vaccine in pigs against experimental infection and under field conditions. Vaccine. 2019. PMID: 30867100. doi:10.1016/j.vaccine.2019.02.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。